Payment overview · 2025
General Payments
$160.40
3 reported records · 3 companies
Healthcare provider profile · identity verified
Jesus S Gallegos, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1851327621
Verified facts
What the public records show
CMS Open Payments records show Jesus S Gallegos, MD received $160.40 in general payments during 2025 across 3 reported records.
Alexion Pharmaceuticals, Inc. accounted for 77.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.98 | 77.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.21 | 13.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.21 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $160.40 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 709 | 236 |
| Losartan Potassium | Losartan Potassium | 476 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 460 | 141 |
| Metformin Hcl | Metformin Hcl | 369 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 103 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 237 | 70 |
| Tramadol Hcl | Tramadol Hcl | 191 | 73 |
| Omeprazole | Omeprazole | 175 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 58 |
| Lisinopril | Lisinopril | 167 | 61 |
| Gabapentin | Gabapentin | 149 | 61 |
| Simvastatin | Simvastatin | 141 | 42 |
| Trazodone Hcl | Trazodone Hcl | 139 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 46 |
| Jardiance | Empagliflozin | 122 | 33 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 115 | 27 |
| Mounjaro | Tirzepatide | 115 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 49 |
| Carvedilol | Carvedilol | 106 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 42 |
| Finasteride | Finasteride | 104 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 104 | 33 |
| Trulicity | Dulaglutide | 95 | 24 |
| Alendronate Sodium | Alendronate Sodium | 92 | 28 |
| Montelukast Sodium | Montelukast Sodium | 91 | 29 |
| Alprazolam | Alprazolam | 89 | 25 |
| Sertraline Hcl | Sertraline Hcl | 86 | 33 |
| Eliquis | Apixaban | 80 | 25 |
| Nifedipine Er | Nifedipine | 79 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 35 |
| Glipizide | Glipizide | 77 | 21 |
| Furosemide | Furosemide | 75 | 34 |
| Clonazepam | Clonazepam | 74 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 30 |
| Valsartan | Valsartan | 74 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 29 |
| Terazosin Hcl | Terazosin Hcl | 66 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 25 |
| Bupropion Xl | Bupropion Hcl | 59 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 25 |
| Potassium Chloride | Potassium Chloride | 55 | 22 |
| Pregabalin | Pregabalin | 55 | 14 |
| Myrbetriq | Mirabegron | 54 | 16 |
| Temazepam | Temazepam | 53 | 12 |
| Donepezil Hcl | Donepezil Hcl | 51 | 23 |
| Methylprednisolone | Methylprednisolone | 50 | 49 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 18 |
| Allopurinol | Allopurinol | 46 | 17 |
| Ezetimibe | Ezetimibe | 46 | 15 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 13 |
| Azithromycin | Azithromycin | 43 | 42 |
| Clonidine Hcl | Clonidine Hcl | 43 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 17 |
| Januvia | Sitagliptin Phosphate | 43 | 19 |
| Ozempic | Semaglutide | 43 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 17 |
| Celecoxib | Celecoxib | 39 | 13 |
| Ibuprofen | Ibuprofen | 39 | 35 |
| Fenofibrate | Fenofibrate | 38 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 11 |
| Spironolactone | Spironolactone | 36 | 12 |
| Famotidine | Famotidine | 35 | 17 |
| Lorazepam | Lorazepam | 35 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 32 |
| Mirtazapine | Mirtazapine | 34 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 33 | 11 |
| Diazepam | Diazepam | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Farxiga | Dapagliflozin Propanediol | 31 | 12 |
| Ketoconazole | Ketoconazole | 31 | 12 |
| Nystatin | Nystatin | 31 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Prednisone | Prednisone | 28 | 17 |
| Baclofen | Baclofen | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | 13 |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Ciclopirox | Ciclopirox | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 14 |
| Risperidone | Risperidone | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Clotrimazole | Clotrimazole | 21 | 16 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Irbesartan | Irbesartan | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $160.40 · 3 records | Alexion Pharmaceuticals, Inc. | CAPVAXIVE, OTEZLA, REPATHA, ULTOMIRIS | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error